Bluebird Bio Top Management

BLUEDelisted Stock  USD 4.97  0.23  4.85%   
Bluebird Bio employs about 248 people. The company is managed by 16 executives with a total tenure of roughly 8 years, averaging almost 0.0 years of service per executive, having 15.5 employees per reported executive. Evaluation of Bluebird Bio's management performance can provide insight into the firm performance.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Bluebird Bio Management Team Effectiveness

The company has return on total asset (ROA) of (0.2837) % which means that it has lost $0.2837 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.4654) %, meaning that it created substantial loss on money invested by shareholders. Bluebird Bio's management efficiency ratios could be used to measure how well Bluebird Bio manages its routine affairs as well as how well it operates its assets and liabilities.
The market capitalization of Bluebird Bio is $48.67 Million. 30% of Bluebird Bio outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in stocks such as Bluebird Bio in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Bluebird Bio, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Bluebird Bio Workforce Comparison

Bluebird Bio is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 730. Bluebird Bio totals roughly 248 in number of employees claiming about 34% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.92) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.56) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.56.

Bluebird Bio Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluebird Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluebird Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bluebird Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bluebird Bio Notable Stakeholders

A Bluebird Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bluebird Bio often face trade-offs trying to please all of them. Bluebird Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bluebird Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Andrew ObenshainCEO PresidentProfile
Oliver IIICFO OfficerProfile
Elizabeth PingpankDirector CommunicationsProfile
Mr MDChief OfficerProfile
Melissa BonnerVP ResearchProfile
Andrea WaltonChief OfficerProfile
JD EsqChief SecretaryProfile
Christopher CPAPrincipal CFOProfile
Richard MDChief OfficerProfile
Courtney OLearyInvestor OfficerProfile
Jess RowlandsHead CommunicationsProfile
Liviu MDVP AffairsProfile
Kasra KasraianRegulatory QualityProfile
Scott ShoemakerSenior OperationsProfile
Sarah AlspachSenior AffairsProfile
Thomas KlimaChief OfficerProfile
String symbol = request.getParameter("s");

About Bluebird Bio Management Performance

The success or failure of an entity such as Bluebird Bio often depends on how effective the management is. Bluebird Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bluebird management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bluebird management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts. Bluebird Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 518 people.
Please note, the presentation of Bluebird Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bluebird Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bluebird Bio's management manipulating its earnings.

Bluebird Bio Workforce Analysis

Traditionally, organizations such as Bluebird Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bluebird Bio within its industry.

Bluebird Bio Manpower Efficiency

Return on Bluebird Bio Manpower

Revenue Per Employee337.9K
Revenue Per Executive5.2M
Net Loss Per Employee970.6K
Net Loss Per Executive15M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Consideration for investing in Bluebird Stock

If you are still planning to invest in Bluebird Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bluebird Bio's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets